Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Caribou Biosciences (CRBU) Other Non Operating Income (2020 - 2025)

Historic Other Non Operating Income for Caribou Biosciences (CRBU) over the last 6 years, with Q3 2025 value amounting to $1.9 million.

  • Caribou Biosciences' Other Non Operating Income fell 5018.83% to $1.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $9.8 million, marking a year-over-year decrease of 4248.0%. This contributed to the annual value of $15.3 million for FY2024, which is 78.86% down from last year.
  • Per Caribou Biosciences' latest filing, its Other Non Operating Income stood at $1.9 million for Q3 2025, which was down 5018.83% from $2.2 million recorded in Q2 2025.
  • Caribou Biosciences' 5-year Other Non Operating Income high stood at $4.8 million for Q4 2023, and its period low was $16000.0 during Q1 2021.
  • In the last 5 years, Caribou Biosciences' Other Non Operating Income had a median value of $2.5 million in 2022 and averaged $2.4 million.
  • In the last 5 years, Caribou Biosciences' Other Non Operating Income tumbled by 7889.91% in 2021 and then skyrocketed by 315777.78% in 2022.
  • Quarter analysis of 5 years shows Caribou Biosciences' Other Non Operating Income stood at $45000.0 in 2021, then skyrocketed by 5080.0% to $2.3 million in 2022, then surged by 106.61% to $4.8 million in 2023, then crashed by 34.47% to $3.2 million in 2024, then tumbled by 41.32% to $1.9 million in 2025.
  • Its Other Non Operating Income stands at $1.9 million for Q3 2025, versus $2.2 million for Q2 2025 and $2.6 million for Q1 2025.